Biryukova E.V., Kapustina L.A. Monitoring glycemic control is the main part of successful treatment of diabetes mellitus. Consilium Medicum. 2017; 19 (10): 132–136. DOI: 10.26442/2075-1753_19.10.132-136
Самоконтроль гликемии – неотъемлемый компонент успешного лечения сахарного диабета
Biryukova E.V., Kapustina L.A. Monitoring glycemic control is the main part of successful treatment of diabetes mellitus. Consilium Medicum. 2017; 19 (10): 132–136. DOI: 10.26442/2075-1753_19.10.132-136
Сахарный диабет (СД) остается актуальной проблемой медицины XXI в., связанной с развитием сосудистых осложнений, определяющих прогноз жизни. В предотвращении хронических осложнений ведущую роль играет достижение гликемического контроля, что практически невозможно без полноправного участия самого пациента в лечении СД. Самоконтроль гликемии – основа эффективности сахароснижающей терапии и профилактики гипогликемии. Обсуждаются результаты исследований, которые продемонстрировали, что увеличение частоты самоконтроля приводит к снижению уровня гликированного гемоглобина у пациентов с СД. Выбор качественного глюкометра определяется простотой использования, удобством работы прибора, легкостью получения результата и достоверностью полученных результатов измерения.
Diabetes mellitus (DM) remains main problem of medicine in the 21st century, associated with the development of vascular complications that define prognosis and life expectancy. The major role in preventing chronic complications plays achieving glycemic control that is practically impossible without full patient participation in DM treatment. Monitoring glycemic control is the basis of the efficacy of antihyperglycemic therapy and prevention of hypoglycemia. The article discusses the results of studies and shows that the increase in the frequency of monitoring of blood glucose leads to a decrease of glycated hemoglobin levels in patients with DM. The selection of the best blood glucose meters is defined by its ease of use, ease of operation, and ease of obtaining results and of obtaining statistically significant results.
1. International Diabetes Federation. IDF Diabetes Atlas Seventh Edition http://www.diabetesatlas.org/
2. Dedov II, Shestakova MV, Benedetti MM et al. Prevalence of Type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabet Res Clin Pract 2016; 115: 90–5.
3. Duckworth WC, McCarren M, Abraira С. Glucose Control and Cardiovascular Complications: The VA Diabetes Tria. Diabetes Care 2001; 24 (5): 942–5.
4. Bouche JL, Hurrell DJ. Cardiovascular Disease and Diabetes. Diabet spectrum 2008; 21 (3): 54–5.
5. Orchard TJ, Costacou T, Kretowski A, Nesto R. W Type 1 Diabetes and Coronary Artery Disease. Diabetes Care 2006; 29 (11): 2528–38.
6. Bartnik M, Ryden L, Ferrari R et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004; 25 (21): 1880–90.
7. Kengne AP, Patel A, Marre M et al. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. Eur J of Cardiovasc Prevent Rehab 2011; 18: 393–8.
8. Khaled AA, Sekaran M, Ikram SI. Type 2 diabetes and vascular complications: A pathophysiologic view. Biomed Res 2010; 21 (2): 147–50.
9. Milicevic Z, Raz I, Beattie SD et al. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care 2008; 31 (2): S155–S160.
10. Zoungas S, Patel A. Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies. Ann N Y Acad Sci 2010; 1212 (1): 29–40.
11. Larsen J, Brekke M, Sandvik L et al. Silent coronary atheromatosis in type 1 diabetic patients and its relation to long-term glycemic control. Diabetes 2002; 51: 2637–41.
12. Massi-Benedetti M. The Cost of Diabetes in Europe – Type II: the CODE-2 Study. Diabetolody 2002; 45 (7): S1–4.
13. Duckworth WC, McCarren M, Abraira С. Glucose Control and Cardiovascular Complications: The VA Diabetes Tria. Diabetes Care 2001; 24 (5): 942–5.
14. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–89.
15. Аметов А.С., Черникова Н.А. Гликемический контроль у пациентов с сахарным диабетом типа 2. Consilium Medicum. 2016; 18 (4): 24–7. / Ametov A.S., Chernikova N.A. Glikemicheskij kontrol' u pacientov s saharnym diabetom tipa 2. Consilium Medicum. 2016; 18 (4): 24–7. [in Russian]
16. Майоров А.Ю., Мельникова О.Г., Филиппов Ю.И. Вопросы самоконтроля гликемии в практике лечения сахарного диабета. Справочник поликлинического врача. 2012; 12: 32–6. / Maiorov A.Iu., Mel'nikova O.G., Filippov Iu.I. Voprosy samokontrolia glikemii v praktike lecheniia sakharnogo diabeta. Handbook for Practitioners Doctors. 2012; 12: 32–6. [in Russian]
17. Blonde L, Karter AJ. Current evidence regarding the value of self monitored blood glucose testing. Am J Med 2005; 118 (Suppl. 9A): 20S–6S.
18. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983–2005). Arch Intern Med 2009; 169 (14): 1307–16.
19. Рунова Г.Е. Самоконтроль гликемии при сахарном диабете: медицинские и психологические аспекты. Consilium Medicum. 2016; 18 (5): 98–102. / Runova G.E. Samokontrol' glikemii pri sakharnom diabete: meditsinskie i psikhologicheskie aspekty. Consilium Medicum. 2016; 18 (5): 98–102. [in Russian]
20. McGeoch G, Derry S, Moore RA. Self-monitoringof blood glucose in type-2 diabetes: what is the evidence? Diabetes Metab Res Rev 2007; 23: 423–40.
21. Miller KM, Beck RW, Bergenstal RM et al. Evidence of a Strong Association Between Frequency of Self-Monitoring of Blood Glucose and Hemoglobin A1c Levels in T1D Exchange Clinic Registry Participants. Diabetes Care 2013; 36 (7): 2009–14.29: 2528–38.
22. Bosi E, Scavini M, Ceriello A et al. Structured SMBG Improves HbA1c Through targeted changes in diabetes therapy in patients with non-insulin treated type 2 diabetes: the PRISMA study. Diabetes 2012; 61 (Suppl. 1): A212.
23. O’Kane MJ, Bunting B, Copeland M et al. Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial. BMJ 2008; 336: 1174–7.
24. Clar C et al. Self-monitoring of blood glucose in type 2 diabetes: systematic review. Health Technol Assess 2010; 14 (12).
25. Farmer A, Wade A, Goyder E et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ 2007; 335: 13–8.
26. ORIGIN Trial Investigators, Gerstein H, Yusuf S et al. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008; 155 (1): 26–32.
27. Polonsky WH, Fisher L, Schikman CH et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes. Results from the structured testing program study. Diabetes Care 2011; 34: 262–7.
28. Neisser K, Weber C, Wenzel H, Schneider B. Costs of self-measurement of blood glucose (SMBG) regarding morbidity and mortality in type 2 diabetes in a reality of care setting (The ROSSO study No 6). The European Association for the Study of Diabetes. Abstract Volume 42st Annual Meeting, Copenhagen, Malmoe. 2006: p. 141.
29. Patton SR. Adherence to Glycemic Monitoring in Diabetes. J Diabetes Sci Techno 2015; 9 (3): 668–75.
30. Hansen MV, Pedersen-Bjergaard U, Heller SR et al. Frequency and motives of blood glucose self-monitoring in type 1 diabetes. Diabetes Res Clin Pract 2009; 85: 183–8.
31. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой. 8-й вып. М., 2017. / Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym sakharnym diabetom. Pod red. I.I.Dedova, M.V.Shestakovoi. 8-i vyp. M., 2017. [in Russian]
32. Snell-Bergeon JK, Wadwa RP. Hypoglycemia, diabetes, and cardiovascular disease. Diabetes Technol Ther 2012; 14 (Suppl. 1): S51–S58.
33. Goto A, Arah OA, Goto M et al. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 2013; 29 (347): f4533.
34. Graveling AJ, Frier BM. Impaired awareness of hypoglycaemia: a review. Diabetes Metab 2010; 36 (Suppl. 3): S64–74. DOI: 10.1016/S1262-3636(10)70470-5
35. Schmid C, Haug C, Heinemann L, Freckmann G. System Accuracy of Blood Glucose Monitoring Systems: Impact of Use by Patients and Ambient Conditions. Diabetes Technol Ther 2013; 15 (10): 889–96.
36. Kuo CY, Hsu CT, Ho CS et al. Accuracy and precision evaluation of seven self-monitoring blood glucose systems. Diabetes Technol Ther 2011; 13: 596–600.
37. Freckmann G, Schmid C, Baumstark A et al. System accuracy evaluation of 43 blood glucose monitoring systems for self- monitoring of blood glucose according to DIN EN ISO 15197. J Diabetes Sci Technol 2012; 6 (5): 1060–75.
38. International Standard EN ISO 15197:2013. In Vitro diagnostic test systems: Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus. Second Edition 2013-05-15. International Organization for Standardization, 2013.
39. Dunne N, Viggiani MT, Pardo S et al. Accuracy Evaluation of CONTOUR®PLUS Compared With Four Blood Glucose Monitoring Systems. Diabetes Ther 2015; 6 (3): 377–88.
40. Кочергина И.И. Контроль гликемии у больных сахарным диабетом и кардиальной патологией. Consilium Medicum. 2017; 19 (1): 56–60. / Kochergina I.I. Kontrol' glikemii u bol'nykh sakharnym diabetom i kardial'noi patologiei. Consilium Medicum. 2017; 19 (1): 56–60. [in Russian]
________________________________________________
1. International Diabetes Federation. IDF Diabetes Atlas Seventh Edition http://www.diabetesatlas.org/
2. Dedov II, Shestakova MV, Benedetti MM et al. Prevalence of Type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabet Res Clin Pract 2016; 115: 90–5.
3. Duckworth WC, McCarren M, Abraira С. Glucose Control and Cardiovascular Complications: The VA Diabetes Tria. Diabetes Care 2001; 24 (5): 942–5.
4. Bouche JL, Hurrell DJ. Cardiovascular Disease and Diabetes. Diabet spectrum 2008; 21 (3): 54–5.
5. Orchard TJ, Costacou T, Kretowski A, Nesto R. W Type 1 Diabetes and Coronary Artery Disease. Diabetes Care 2006; 29 (11): 2528–38.
6. Bartnik M, Ryden L, Ferrari R et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004; 25 (21): 1880–90.
7. Kengne AP, Patel A, Marre M et al. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. Eur J of Cardiovasc Prevent Rehab 2011; 18: 393–8.
8. Khaled AA, Sekaran M, Ikram SI. Type 2 diabetes and vascular complications: A pathophysiologic view. Biomed Res 2010; 21 (2): 147–50.
9. Milicevic Z, Raz I, Beattie SD et al. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care 2008; 31 (2): S155–S160.
10. Zoungas S, Patel A. Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies. Ann N Y Acad Sci 2010; 1212 (1): 29–40.
11. Larsen J, Brekke M, Sandvik L et al. Silent coronary atheromatosis in type 1 diabetic patients and its relation to long-term glycemic control. Diabetes 2002; 51: 2637–41.
12. Massi-Benedetti M. The Cost of Diabetes in Europe – Type II: the CODE-2 Study. Diabetolody 2002; 45 (7): S1–4.
13. Duckworth WC, McCarren M, Abraira С. Glucose Control and Cardiovascular Complications: The VA Diabetes Tria. Diabetes Care 2001; 24 (5): 942–5.
14. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–89.
15. Ametov A.S., Chernikova N.A. Glikemicheskij kontrol' u pacientov s saharnym diabetom tipa 2. Consilium Medicum. 2016; 18 (4): 24–7. [in Russian]
16. Maiorov A.Iu., Mel'nikova O.G., Filippov Iu.I. Voprosy samokontrolia glikemii v praktike lecheniia sakharnogo diabeta. Handbook for Practitioners Doctors. 2012; 12: 32–6. [in Russian]
17. Blonde L, Karter AJ. Current evidence regarding the value of self monitored blood glucose testing. Am J Med 2005; 118 (Suppl. 9A): 20S–6S.
18. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983–2005). Arch Intern Med 2009; 169 (14): 1307–16.
19. Runova G.E. Samokontrol' glikemii pri sakharnom diabete: meditsinskie i psikhologicheskie aspekty. Consilium Medicum. 2016; 18 (5): 98–102. [in Russian]
20. McGeoch G, Derry S, Moore RA. Self-monitoringof blood glucose in type-2 diabetes: what is the evidence? Diabetes Metab Res Rev 2007; 23: 423–40.
21. Miller KM, Beck RW, Bergenstal RM et al. Evidence of a Strong Association Between Frequency of Self-Monitoring of Blood Glucose and Hemoglobin A1c Levels in T1D Exchange Clinic Registry Participants. Diabetes Care 2013; 36 (7): 2009–14.29: 2528–38.
22. Bosi E, Scavini M, Ceriello A et al. Structured SMBG Improves HbA1c Through targeted changes in diabetes therapy in patients with non-insulin treated type 2 diabetes: the PRISMA study. Diabetes 2012; 61 (Suppl. 1): A212.
23. O’Kane MJ, Bunting B, Copeland M et al. Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial. BMJ 2008; 336: 1174–7.
24. Clar C et al. Self-monitoring of blood glucose in type 2 diabetes: systematic review. Health Technol Assess 2010; 14 (12).
25. Farmer A, Wade A, Goyder E et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ 2007; 335: 13–8.
26. ORIGIN Trial Investigators, Gerstein H, Yusuf S et al. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008; 155 (1): 26–32.
27. Polonsky WH, Fisher L, Schikman CH et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes. Results from the structured testing program study. Diabetes Care 2011; 34: 262–7.
28. Neisser K, Weber C, Wenzel H, Schneider B. Costs of self-measurement of blood glucose (SMBG) regarding morbidity and mortality in type 2 diabetes in a reality of care setting (The ROSSO study No 6). The European Association for the Study of Diabetes. Abstract Volume 42st Annual Meeting, Copenhagen, Malmoe. 2006: p. 141.
29. Patton SR. Adherence to Glycemic Monitoring in Diabetes. J Diabetes Sci Techno 2015; 9 (3): 668–75.
30. Hansen MV, Pedersen-Bjergaard U, Heller SR et al. Frequency and motives of blood glucose self-monitoring in type 1 diabetes. Diabetes Res Clin Pract 2009; 85: 183–8.
31. Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym sakharnym diabetom. Pod red. I.I.Dedova, M.V.Shestakovoi. 8-i vyp. M., 2017. [in Russian]
32. Snell-Bergeon JK, Wadwa RP. Hypoglycemia, diabetes, and cardiovascular disease. Diabetes Technol Ther 2012; 14 (Suppl. 1): S51–S58.
33. Goto A, Arah OA, Goto M et al. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 2013; 29 (347): f4533.
34. Graveling AJ, Frier BM. Impaired awareness of hypoglycaemia: a review. Diabetes Metab 2010; 36 (Suppl. 3): S64–74. DOI: 10.1016/S1262-3636(10)70470-5
35. Schmid C, Haug C, Heinemann L, Freckmann G. System Accuracy of Blood Glucose Monitoring Systems: Impact of Use by Patients and Ambient Conditions. Diabetes Technol Ther 2013; 15 (10): 889–96.
36. Kuo CY, Hsu CT, Ho CS et al. Accuracy and precision evaluation of seven self-monitoring blood glucose systems. Diabetes Technol Ther 2011; 13: 596–600.
37. Freckmann G, Schmid C, Baumstark A et al. System accuracy evaluation of 43 blood glucose monitoring systems for self- monitoring of blood glucose according to DIN EN ISO 15197. J Diabetes Sci Technol 2012; 6 (5): 1060–75.
38. International Standard EN ISO 15197:2013. In Vitro diagnostic test systems: Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus. Second Edition 2013-05-15. International Organization for Standardization, 2013.
39. Dunne N, Viggiani MT, Pardo S et al. Accuracy Evaluation of CONTOUR®PLUS Compared With Four Blood Glucose Monitoring Systems. Diabetes Ther 2015; 6 (3): 377–88.
40. Kochergina I.I. Kontrol' glikemii u bol'nykh sakharnym diabetom i kardial'noi patologiei. Consilium Medicum. 2017; 19 (1): 56–60. [in Russian]
Авторы
Е.В.Бирюкова*1, Л.А.Капустина2
1 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1;
2 ГБУЗ «Городская поликлиника №69» Департамента здравоохранения г. Москвы. 111401, Россия, Москва, ул. 2-я Владимирская, д. 31А *lena@obsudim.ru
________________________________________________
E.V.Biryukova*1, L.A.Kapustina2
1 A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1;
2 Сity Сlinical Hospital №69 of the Department of Health of the Russian Federation. 111401, Russian Federation, Moscow, ul. 2-ia Vladimirskaia, d. 31A *lena@obsudim.ru